what this node claims
AlphaFold metrics / LEPR
Model-quality receipt for the fold. It is not biological validation.
vertical proof spine
evidence / risk instrument
50%
low debt pressure
24%
66%structureusable
pLDDT 66.02
78%evidenceusable
grade B
0%gatesdebt
0/5 gates
100%riskstrong
0 hard flags
22%exportdebt
no export
33%lineagedebt
incomplete spine
proof completeness
33% missing target, candidate, finding, export- 01 target
- 02 fold
- 03 alphafold metric
- 04 candidate
- 05 finding
- 06 export
Metrics and receipt inputs
- confidence band
- low
- confidence pct
- 66.02
- coverage context
- missing or not linked
- interpretation
- weak structural context; downstream claims should be conservative
- pae context
- missing or not linked
- plddt avg
- 66.02
- sequence length
- 0
AlphaFold metrics visual
Low-confidence regions present
1165 residues / min 20.67 / max 96.69 / source alphafold db
Very high
20.9%
243 residues / >=90
Confident
36.7%
427 residues / 70-89
Low
9.7%
113 residues / 50-69
Very low
32.8%
382 residues / <50
weak structural context; downstream claims should be conservative
Near-complete coverage / observed 1165 of 1165 residues.
- residues 864-1165 / mean 32.53
- residues 38-88 / mean 33.99
- residues 91-125 / mean 42.48
- residues 1-32 / mean 48.83
proof debt register
24%
Visible limits, not hidden cleanup.
Peptide RX keeps unresolved proof debt attached to the public receipt. Some debts should be resolved; redaction and research-use boundaries should stay visible.